• KOL
    • Venous Thromboembolism
    • Silvy Laporte
    • Silvy Laporte: Influence Statistics

      Silvy Laporte

      Silvy Laporte

      Show email address

      SAINBIOSE INSERM U1059, Université Jean Monnet, Saint-Etienne, France | Unité de Recherche Clinique Innovation et Pharmacologie, CHU Saint-Etienne, Saint-Etienne, France | ...

      Is this your profile? manage_accounts Claim your profile content_copy Copy URL code Embed Link to your profile

      Silvy Laporte:Expert Impact

      Concepts for whichSilvy Laportehas direct influence:Venous thromboembolism,Pulmonary embolism,Observational studies,Major bleeding,6 months,New oral anticoagulants,Major orthopaedic surgery,Renal impairment.

      Silvy Laporte:KOL impact

      Concepts related to the work of other authors for whichfor which Silvy Laporte has influence:Venous thromboembolism,Pulmonary embolism,Elderly patients,Tranexamic acid,Vena cava,Lung cancer,Blood loss.

      KOL Resume for Silvy Laporte

      Year
      2021

      SAINBIOSE INSERM U1059, Université Jean Monnet, Saint-Etienne, France

      2020

      Université Jean Monnet, Université de Lyon, SAINBIOSE INSERM U1059, F-42023 Saint-Etienne, France;,

      Unité de Recherche Clinique, Innovation, Pharmacologie, Hôpital Nord, CHU de Saint-Etienne, Saint-Etienne, France

      2019

      SAINBIOSE INSERM U1059, Université Jean Monnet, Université de Lyon, Unité de Recherche Clinique, Innovation, Pharmacologie, Saint-Etienne, France

      2018

      F-CRIN INNOVTE, Saint-Étienne, France

      2017

      INSERM UMR 1059, Saint Etienne University Jean Monnet, Saint Etienne, France

      2016

      CHU Saint-Etienne, Unité de Recherche Clinique et d’Innovation Pharmacologique, Saint-Etienne, France

      2015

      University Hospital of Saint-Etienne-Hospital Nord, Saint-Etienne, France.

      Groupe d’Investigation et de Recherche Clinique sur la Thrombose (GIRC Thrombose)

      Unité de Pharmacologie Clinique, Centre Hospitalier Universitaire de Saint-Etienne, France

      2014

      Unité de Recherche Clinique, Innovation et Pharmacologie, CHU Saint-Etienne, France

      Sign-in to see all concepts, it's free!
      Sample of concepts for which Silvy Laporte is among the top experts in the world.
      Concept World rank
      pathway inhibitor activity #1
      pulmonary embolism symptoms #1
      low varicose #1
      markers screening strategy #1
      grade elastic stockings #1
      rheso study #1
      cancer antiplatelet therapy #1
      bleeding nonmajor #1
      angiopred #1
      grade digestive #1
      rrt therapy #1
      assay function tests #1
      symptomatic incidental dvt #1
      angiopred study #1
      moderate risk situation #1
      efficious grade #1
      22 palliative units #1
      highrisk women angiopred #1
      delivery highrisk women #1
      doacs lowmolecularweight heparin #1
      grade highrisk surgery #1
      risk terminally patients #1
      45664 subjects #1
      extension 1 month #1
      newborn lipoproteins placentamediated #1
      function tests lta #1
      palliative units risk #1
      fondaparinux administered #2
      hazard major bleeding #2
      vte r2trial #2
      platelet α2adrenoreceptor #2
      4000 antixa iu #2
      ncb mortality #2
      4036 patients #2
      oncedaily subcutaneous dose #2
      semi‐mechanistic absorption #2
      thrombosis multifactorial disease #2
      44 randomised comparisons #2
      200 pregnant patients #2
      daily 3000 #2
      safety outcome incidence #2
      surrogate outcome causemortality #2
      même niveau #2
      clopidogrel 20 #2
      Sign-in to see all concepts, it's free!

      Prominent publications by Silvy Laporte

      KOL-Index: 17367

      IMPORTANCE: Although retrievable inferior vena cava filters are frequently used in addition to anticoagulation in patients with acute venous thromboembolism, their benefit-risk ratio is unclear.

      OBJECTIVE: To evaluate the efficacy and safety of retrievable vena cava filters plus anticoagulation vs anticoagulation alone for preventing pulmonary embolism recurrence in patients presenting with acute pulmonary embolism and a high risk of recurrence.

      DESIGN, SETTING, AND PARTICIPANTS: ...

      Known for Recurrent Pulmonary Embolism | Cava Filter | Anticoagulation Patients | 3 Months | Retrievable Inferior
      KOL-Index: 16680

      BACKGROUND: Platinum-based doublet chemotherapy is recommended to treat advanced non-small-cell lung cancer (NSCLC) in fit, non-elderly adults, but monotherapy is recommended for patients older than 70 years. We compared a carboplatin and paclitaxel doublet chemotherapy regimen with monotherapy in elderly patients with advanced NSCLC.

      METHODS: In this multicentre, open-label, phase 3, randomised trial we recruited patients aged 70-89 years with locally advanced or metastatic NSCLC and ...

      Known for Doublet Chemotherapy | Elderly Patients | 3 Trial | Cell Lung | Antineoplastic Agents
      KOL-Index: 14604

      IMPORTANCE: The optimal duration of anticoagulation after a first episode of unprovoked pulmonary embolism is uncertain.

      OBJECTIVES: To determine the benefits and harms of an additional 18-month treatment with warfarin vs placebo, after an initial 6-month nonrandomized treatment period on a vitamin K antagonist.

      DESIGN, SETTING, AND PARTICIPANTS: Randomized, double-blind trial (treatment period, 18 months; median follow-up, 24 months); 371 adult patients who had experienced a first ...

      Known for Major Bleeding | Warfarin Placebo | 18 Months | Extended Oral Anticoagulation | Episode Pulmonary Embolism
      KOL-Index: 14448

      BACKGROUND: The efficacy and safety of vena caval filters in the prevention of pulmonary embolism in patients with proximal deep-vein thrombosis is still a matter of debate.

      METHODS: Using a two-by-two factorial design, we randomly assigned 400 patients with proximal deep-vein thrombosis who were at risk for pulmonary embolism to receive a vena caval filter (200 patients) or no filter (200 patients), and to receive low-molecular-weight heparin (enoxaparin, 195 patients) or unfractionated ...

      Known for Pulmonary Embolism | Vena Caval Filters | Vein Thrombosis | Proximal Deep | Clinical Trial
      KOL-Index: 12203

      BACKGROUND: The efficacy and safety of anticoagulant treatment for patients with acute, symptomatic superficial-vein thrombosis in the legs, but without concomitant deep-vein thrombosis or symptomatic pulmonary embolism at presentation, have not been established.

      METHODS: In a randomized, double-blind trial, we assigned 3002 patients to receive either fondaparinux, administered subcutaneously at a dose of 2.5 mg once daily, or placebo for 45 days. The primary efficacy outcome was a ...

      Known for Vein Thrombosis | Pulmonary Embolism | Fondaparinux Placebo | Primary Efficacy Outcome | Major Bleeding
      KOL-Index: 11580

      OBJECTIVES: The purpose of this study was to investigate the survival effects of inferior vena cava filters in patients with venous thromboembolism (VTE) who had a significant bleeding risk.

      BACKGROUND: The effectiveness of inferior vena cava filter use among patients with acute symptomatic VTE and known significant bleeding risk remains unclear.

      METHODS: In this prospective cohort study of patients with acute VTE identified from the RIETE (Computerized Registry of Patients With Venous ...

      Known for Vena Cava | Venous Thromboembolism | Bleeding Risk | Filter Insertion | Patients Acute Vte
      KOL-Index: 11248

      INTRODUCTION: To compare the impact on overall survival (OS) of docetaxel-based chemotherapy versus vinca alkaloid-based regimens for first-line therapy of advanced non-small cell lung cancer.

      METHODS: A meta-analysis of all randomized, controlled trials comparing docetaxel- and vinca alkaloid-based chemotherapy was undertaken using MEDLINE, CANCERLIT, MEDSCAPE, Google Scholar, the Cochrane Library, the National Institutes of Health randomized, controlled trials register, and conference ...

      Known for Vinca Alkaloid | Cell Lung | Based Chemotherapy | Safety Docetaxel | Firstline Therapy
      KOL-Index: 11111

      STUDY OBJECTIVES: Low-molecular-weight heparins have been compared with unfractionated heparin (UFH) for treatment of deep vein thrombosis (DVT). However, a comparison of their efficacy in the presence or absence of pulmonary embolism (PE) has not been studied. We estimated the efficacy and safety of enoxaparin vs UFH in patients with proximal DVT with/without symptomatic PE using a meta-analysis of individual data from randomized controlled trials.

      DESIGN AND SETTING: Randomized ...

      Known for Deep Vein Thrombosis | Ufh Vte | Pulmonary Embolism | Major Bleeding | Enoxaparin Treatment
      KOL-Index: 10344

      BACKGROUND: The optimal thromboprophylactic dosage regimen of low-molecular-weight heparins in high-risk general surgery remains debatable.

      OBJECTIVES: We performed a randomized, double-blind study to compare the efficacy and safety of nadroparin 2850 IU (0.3 mL) and enoxaparin 4000 IU (40 mg) in the prevention of venous thromboembolism (VTE) after colorectal surgery for cancer.

      PATIENTS AND METHODS: Patients undergoing resection of colorectal adenocarcinoma were randomized to receive ...

      Known for Colorectal Surgery | Symptomatic Vte | Efficacy Safety | Major Bleeding | Venous Thromboembolism
      KOL-Index: 10118

      BACKGROUND: Low molecular weight heparins (LMWHs) have become routine thromboprophylaxis in general surgery. However, their actual clinical effect, its magnitude relative to that of unfractionated heparin (UFH), and the optimal dose are still debated.

      METHODS: A meta-analysis was performed of all available randomized trials in general surgery comparing LMWH with placebo or no treatment, or with UFH.

      RESULTS: Comparison versus placebo or no treatment confirmed that the significant ...

      Known for General Surgery | Molecular Weight | Lmwh Ufh | Unfractionated Heparin | Thromboembolism Venous
      KOL-Index: 10087

      Venous thrombosis is a common and severe complication in patients with cancer. We reviewed studies assessing whether a state of acquired or congenital thrombophilia influenced the risk of thrombosis in patients with cancer. The results are equivocal. However, the majority of studies were of limited size. The influence of thrombophilia in patients with cancer may be more difficult to demonstrate than in the general population, the risk of thrombosis due to cancer per se possibly ...

      Known for Venous Thrombosis | Patients Cancer | Thrombophilia Risk | Activated Protein | Factor Leiden
      KOL-Index: 9855

      PURPOSE: Due to its specific pharmacokinetic profile, tinzaparin, a low-molecular-weight heparin (LMWH), appears not to be associated with anti-factor Xa accumulation. Our meta-analysis aimed at determining whether long-term curative doses of tinzaparin is a valuable alternative to vitamin K antagonists (VKA) for the treatment of symptomatic venous thromboembolism (VTE), especially in patients with cancer who are at higher risk of recurrence and bleeding.

      MATERIALS AND METHODS: A ...

      Known for Venous Thromboembolism | Term Treatment | Vte Patients | Major Bleeding | Vitamin Antagonists
      KOL-Index: 9744

      BACKGROUND: Clinical predictors for fatal pulmonary embolism (PE) in patients with venous thromboembolism have never been studied.

      METHODS AND RESULTS: Using data from the international prospective Registro Informatizado de la Enfermedad TromboEmbolica venosa (RIETE) registry about patients with objectively confirmed symptomatic acute venous thromboembolism, we determined independent predictive factors for fatal PE. Between March 2001 and July 2006, 15 520 consecutive patients (mean ...

      Known for Venous Thromboembolism | Fatal Pulmonary Embolism | Patients Symptomatic | Riete Registry | 3 Months
      KOL-Index: 9413

      While laboratory monitoring is not required in patients treated with apixaban, a direct factor-Xa inhibitor, assessment of its concentration is useful in some critical situations. However, few data are available on its effect on coagulation tests and on the suitability of anti-Xa assays for its quantification. It was the objective of this study to identify laboratory tests suitable for apixaban concentration assessment. Coagulation tests - PT and aPTT- and anti-Xa assays were performed ...

      Known for Laboratory Tests | Aptt Apixaban | Antixa Assays | Large Panel | Prothrombin Time

      Key People For Venous Thromboembolism

      Top KOLs in the world
      #1
      John A Heit
      venous thromboembolism pulmonary embolism alcohol dependence
      #2
      Harry Roger Büller
      pulmonary embolism venous thrombosis major bleeding
      #3
      Paolo Prandoni
      venous thromboembolism pulmonary embolism vein thrombosis
      #4
      Samuel Zachary Goldhaber
      pulmonary embolism atrial fibrillation major bleeding
      #5
      Martin Hendrik Prins
      venous thromboembolism pulmonary embolism intermittent claudication
      #6
      Giancarlo Agnelli
      venous thromboembolism pulmonary embolism atrial fibrillation

      SAINBIOSE INSERM U1059, Université Jean Monnet, Saint-Etienne, France | Unité de Recherche Clinique Innovation et Pharmacologie, CHU Saint-Etienne, Saint-Etienne, France | Saint‐Etienne, UMR1059, Université Jean‐Monnet, Saint‐Etienne, France | CHU de

    Download on the App StoreGet it on Google Play

    Copyright © 2023 Key Opinion Leaders, LLC.